Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Phase 2 Completed
50 enrolled 13 charts
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Phase 1/2 Completed
34 enrolled 22 charts
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase 2 Completed
73 enrolled 16 charts
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Phase 2 Completed
60 enrolled 10 charts
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase 1/2 Terminated
3 enrolled 15 charts
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Phase 1/2 Completed
92 enrolled 28 charts
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Phase 2 Withdrawn
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
12 enrolled 10 charts
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase 2 Terminated
14 enrolled 7 charts
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Phase 2 Completed
204 enrolled 7 charts
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Phase 2 Completed
25 enrolled
REGALE
Phase NA Terminated
24 enrolled 7 charts
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
Phase 2 Completed
2 enrolled
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
Phase 2 Unknown
49 enrolled
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 2 Unknown
47 enrolled
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Phase 1/2 Completed
24 enrolled
Campath-1H + FK506 and Methylprednisolone for GVHD
Phase 2 Completed
34 enrolled
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Phase 2 Completed
53 enrolled